{"product_id":"gfp-expressing-rgd-fiber-modified-adenovirus-adrgd-cmv-gfp-bhv21600336","title":"GFP expressing RGD fiber modified Adenovirus (Ad(RGD)-CMV-GFP)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAd(RGD)-CMV-GFP is a replication-defective recombinant Ad5 adenovirus expressing the GFP reporter gene under the CMV promoter. Reporter adenoviruses are commonly used to benchmark transduction efficiency, titrate MOI in new cell or animal models, and as transduction-load controls for paired over-expression vectors.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBackbone:\u003c\/strong\u003e Human adenovirus type 5 (Ad5) with E1 and E3 deleted (dE1\/E3). Replication-incompetent in standard cells; replication-competent helper cells (HEK293) are required for amplification.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter (CMV):\u003c\/strong\u003e a strong, ubiquitous promoter active in most mammalian cell types.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTransgene:\u003c\/strong\u003e GFP (eGFP tag).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTiter \u0026amp; format:\u003c\/strong\u003e 1×10\u003csup\u003e10\u003c\/sup\u003e PFU\/ml in storage buffer (DMEM, 2% BSA, 2.5% glycerol or equivalent), supplied as a 200 µL aliquot.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eAd infection is initiated by recognition of the native Ad5 receptor, coxsackievirus-adenovirus receptor (CAR), on target cells by the carboxy-terminal portion (i.e., knob) of the fiber protein. Therefore the infection efficiency of adenovirus is very low for cells with low or no CAR receptors. Arg-Gly-Asp (RGD) motif was introduced in the surface-exposed loops of adenovirus fiber knob, this enables the adenovirus to bypass CAR and mediate cell entry via RGD binding integrins. So the RDG modified adenovirus can be used for “retargeting” cells that regular adenovirus doesn’t work well. The infection effeciency of RDG modified adenovirus can be tens or hundreds of times higher than standard Ad5 in some cells, including human or mouse macrophages, T cells, synoviocytes, islet grafts, adipocytes, MEF, etc.\u003c\/p\u003e\u003cp\u003eThis is a RGD modified replication-deficient adenovirus expressing eGFP under a CMV promoter.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eDecision-relevant for researchers studying Reporter Vectors.\u003c\/li\u003e\n\u003cli\u003eAdenovirus-mediated delivery is well-established in primary cells, organoids, and small-animal models.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eTransduction-efficiency benchmarking in new cell lines or animal models.\u003c\/li\u003e\n\u003cli\u003eMOI titration as a positive control before switching to a transgene of interest.\u003c\/li\u003e\n\u003cli\u003ePromoter-activity readout for transcriptional studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eAdenoviral delivery is episomal and non-integrating; expression dilutes with cell division and typically lasts 1–2 weeks in dividing cells (longer in non-dividing cells such as hepatocytes, neurons, and cardiomyocytes).\u003c\/li\u003e\n\u003cli\u003ePre-existing anti-Ad5 neutralizing antibodies are common in human and primate hosts and can reduce in vivo transduction; this is less relevant in inbred laboratory mouse strains.\u003c\/li\u003e\n\u003cli\u003eMOI optimization is essential — over-dosing can cause cytopathic effects; under-dosing yields incomplete transduction. A 3–5× MOI titration in your specific cell or animal model is recommended.\u003c\/li\u003e\n\u003cli\u003eReplication-defective Ad5 vectors are typically handled at BSL-2; consult your institutional biosafety officer for specific transgenes and routes of use.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal):\n  - NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n  - UniProt: https:\/\/www.uniprot.org\/\n  - Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009; 90:1–20.\n  - Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12 Suppl 1:S18–27.\n  - Vendor reference: https:\/\/www.vectorbiolabs.com\/product\/1768-gfp-expressing-rgd-fiber-modified-adenovirus\/\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"1x10^10 PFU\/ml \/ 200 µL","offer_id":53286498697581,"sku":"1768","price":495.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/gfp-expressing-rgd-fiber-modified-adenovirus-adrgd-cmv-gfp-bhv21600336","provider":"BioHippo","version":"1.0","type":"link"}